肝癌的过继性细胞免疫治疗应用的进展研究
Research Progress of Adoptive Cellular Immunotherapy for the Treatment of Hepatocellular Carcinoma
DOI: 10.12677/ACM.2020.1011412, PDF,   
作者: 陈蓁臻：重庆市忠县人民医院，重庆；张爱绮, 龚建平：重庆医科大学附属第二医院，重庆
关键词: 肝癌；免疫细胞；过继治疗；综述；Hepatocellular Carcinoma； Immune Cells； Adoptive Therapy； Review
摘要: 肝细胞肝癌是世界上最常见的恶性肿瘤之一，主要的治疗方式包括手术切除、射频消融、经导管动脉化疗栓塞术(Transarterial chemoembolization, TACE)、放化疗等。目前还有各种相关抗肿瘤的免疫治疗，广泛研究的免疫细胞主要有：树突状细胞(DC)、细胞因子诱导杀伤细胞(CIK)、共培养免疫细胞(DC-CIK)、嵌合抗原受体T细胞(CAR-T)等。治疗措施的选择取决于肿瘤阶段、大小及其肿瘤微环境状态。本文就过继性免疫细胞疗法在肝癌临床治疗中的应用作一综述。
Abstract: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. The main treatment methods include surgical resection, radiofrequency ablation, TACE, chemoradiotherapy and so on. At present, there are a variety of anti-tumor immunotherapies. The immune cells extensively studied include dendritic cells (DC), cytokine induced killer cells (CIK), co-cultured immune cells (DC-CIK), chimeric antigen receptor T cells (CAR-T), etc. The choice of treatment depends on the tumor stage, size, and tumor microenvironmental status. This article reviews the application of adoptive immune cell therapy in the clinical treatment of liver cancer.
文章引用：陈蓁臻, 张爱绮, 龚建平. 肝癌的过继性细胞免疫治疗应用的进展研究[J]. 临床医学进展, 2020, 10(11): 2710-2715. https://doi.org/10.12677/ACM.2020.1011412

参考文献

[1] Sia, D., Jiao, Y., Martinez-Quetglas, I., et al. (2017) Identification of an Immune-Specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology, 153, 812-826. [Google Scholar] [CrossRef] [PubMed]
[2] Dzhandzhugazyan, K.N., Guldberg, P. and Kirkin, A.F. (2018) Adoptive T Cell Cancer Therapy. Nature Materials, 17, 475-477. [Google Scholar] [CrossRef] [PubMed]
[3] Gammaitoni, L., Giraudo, L., Macagno, M., et al. (2017) Cytokine-Induced Killer Cells Kill Chemo-Surviving Melanoma Cancer Stem Cells. Clinical Cancer Research, 23, 2277-2288. [Google Scholar] [CrossRef] 
[4] Cornel, A.M., van Til, N.P., Boelens, J.J., et al. (2018) Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies. Frontiers in Immunology, 9, 982. [Google Scholar] [CrossRef] [PubMed]
[5] Shin, C., Han, J.A., Koh, H., et al. (2015) CD8alpha(-) Dendritic Cells Induce Antigen-Specific T Follicular Helper Cells Generating Efficient Humoral Immune Responses. Cell Reports, 11, 1929-1940. [Google Scholar] [CrossRef] [PubMed]
[6] Dou, L., Ono, Y., Chen, Y.F., et al. (2018) Hepatic Dendritic Cells, the Tolerogenic Liver Environment, and Liver Disease. Seminars in Liver Disease, 38, 170-180. [Google Scholar] [CrossRef] [PubMed]
[7] El Ansary, M., Mogawer, S., Elhamid, S.A., et al. (2013) Immunotherapy by Autologous Dendritic Cell Vaccine in Patients with Advanced HCC. Journal of Cancer Research and Clinical Oncology, 139, 39-48. [Google Scholar] [CrossRef] [PubMed]
[8] Brombacher, E.C. and Everts, B. (2020) Shaping of Dendritic Cell Function by the Metabolic Micro-Environment. Frontiers in Endocrinology (Lausanne), 11, 555. [Google Scholar] [CrossRef] [PubMed]
[9] Dobrovolskienė, N., Pašukonienė, V., Darinskas, A., Kraśko, J.A., Žilionytė, K., Mlynska, A., et al. (2018) Tumor Lysate-Loaded Bacterial Ghosts as a Tool for Optimized Production of Therapeutic Dendritic Cell-Based Cancer Vaccines. Vaccine, 36, 4171-4180. [Google Scholar] [CrossRef] [PubMed]
[10] Sabado, R.L., Balan, S. and Bhardwaj, N. (2017) Dendritic Cell-Based Immunotherapy. Cell Research, 27, 74-95. [Google Scholar] [CrossRef] [PubMed]
[11] Ahmed, M.S. and Bae, Y.S. (2014) Dendritic Cell-Based Therapeutic Cancer Vaccines: Past, Present and Future. Clinical and Experimental Vaccine Research, 3, 113-116. [Google Scholar] [CrossRef] [PubMed]
[12] Chen, J.L., Lao, X.M., Lin, X.J., et al. (2016) Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma after Curative Resection, Medicine (Baltimore), 95, e2665. [Google Scholar] [CrossRef] 
[13] Durrieu, L., Lemieux, W., Dieng, M.M., et al. (2014) Implication of Different Effector Mechanisms by Cord Blood-Derived and Peripheral Blood-Derived Cytokine-Induced Killer Cells to Kill Precursor B Acute Lymphoblastic Leukemia Cell Lines. Cytotherapy, 16, 845-856. [Google Scholar] [CrossRef] [PubMed]
[14] Chen, D., Sha, H., Hu, T., et al. (2018) Cytokine-Induced Killer Cells as a Feasible Adoptive Immunotherapy for the Treatment of Lung Cancer. Cell Death & Disease, 9, Article No. 366. [Google Scholar] [CrossRef] [PubMed]
[15] Yu, B., Wang, J., He, C., et al. (2017) Cytokine-Induced Killer Cell Therapy for Modulating Regulatory T Cells in Patients with Non-Small Cell Lung Cancer. Experimental and Therapeutic Medicine, 14, 831-840. [Google Scholar] [CrossRef] [PubMed]
[16] Pan, K., Li, Y.Q., Wang, W., Xu, L., Zhang, Y.J., Zheng, H.X., et al. (2013) The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients. Annals of Surgical Oncology, 20, 4305-4311. [Google Scholar] [CrossRef] [PubMed]
[17] Schmeel, L.C., Schmeel, F.C., Coch, C. and Schmidt-Wolf, I.G. (2015) Cytokine-Induced Killer (CIK) Cells in Cancer Immunotherapy: Report of the International Registry on CIK Cells (IRCC). Journal of Cancer Research and Clinical Oncology, 141, 839-849. [Google Scholar] [CrossRef] [PubMed]
[18] Yu, R., Yang, B., Chi, X., et al. (2017) Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Immunotherapy for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Drug Design, Development and Therapy, 11, 851-864. [Google Scholar] [CrossRef] 
[19] Lee, J.H., Lee, J.H., Lim, Y.S., Yeon, J.E., Song, T.J., Yu, S.J., Gwak, G.Y., Kim, K.M., Kim, Y.J., Lee, J.W. and Yoon, J.H. (2015) Adjuvant Immunotherapy with Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. Gastroenterology, 148, 1383-1391.e6. [Google Scholar] [CrossRef] [PubMed]
[20] Bonanno, G., Iudicone, P., Mariotti, A., et al. (2010) Thymoglobulin, Interferon-Gamma and Interleukin-2 Efficiently Expand Cytokine-Induced Killer (CIK) Cells in Clinical-Grade Cultures. Journal of Translational Medicine, 8, Article No. 129. [Google Scholar] [CrossRef] [PubMed]
[21] Chen. C.L., Pan, Q.Z., Weng, D.S., et al. (2018) Safety and Activity of PD-1 Blockade-Activated DC-CIK Cells in Patients with Advanced Solid Tumors. Oncoimmunology, 7, e1417721. [Google Scholar] [CrossRef] 
[22] Zhang, J., Li, H., Gao, D., et al. (2018) A Prognosis and Impact Factor Analysis of DC-CIK Celltherapy for Patients with Hepatocellular Carcinoma Undergoing Postoperative TACE. Cancer Biology & Therapy, 19, 475-483. [Google Scholar] [CrossRef] [PubMed]
[23] Ma, Y.J., He, M., Han, J.A., et al. (2013) A Clinical Study of HBsAg-Activated Dendritic Cells and Cytokine-Induced Killer Cells during the Treatment for Chronic Hepatitis B. Scandinavian Journal of Immunology, 78, 387-393. [Google Scholar] [CrossRef] [PubMed]
[24] Brudno, J.N. and Kochenderfer, J.N. (2018) Chimeric Antigen Receptor T-Cell Therapies for Lymphoma. Nature Reviews Clinical Oncology, 15, 31-46. [Google Scholar] [CrossRef] [PubMed]
[25] June, C.H., O’Connor, R.S., Kawalekar, O.U., Ghassemi, S. and Milone, M.C. (2018) CAR T Cell Immunotherapy for Human Cancer. Science, 359, 1361-1365. [Google Scholar] [CrossRef] [PubMed]
[26] Lim, W.A. and June, C.H. (2017) The Principles of Engineering Immune Cells to Treat Cancer. Cell, 168, 724-740. [Google Scholar] [CrossRef] [PubMed]

为你推荐